Genomics deal prompts a debate

Genomics deal prompts a debate

The deal announced last week between Genetic Therapy Inc. and Human Genome Sciences Inc., combining their gene delivery and gene discovery programs, elicited a strong response from competing genetic therapy and genomics companies.

GTII and HGSI defended the deal as solving their mutual needs - to ensure access by the gene therapy company to genes to plug into its vector systems, and to provide an outlet for gene discoveries by the genomics company. The two companies are linked by a common venture capital backer, HealthCare Investment Corp.


But others in the genomics field see this kind of exclusive arrangement as prematurely tying the genomics company to a limited array of gene delivery systems, at a time when the jury is still out on the best vector systems. And some other gene therapy companies believe immediate access to the stream of genes coming out of

Read the full 1480 word article

How to gain access

Continue reading with a
two-week free trial.